Chronic heart failure is a often m...

Chronic heart failure is a often met with and disabling condition for which now passing treatment guidelines recommend combination therapy with diuretics, angiotensin-converting enzyme (ACE) inhibitors, and beta blocker Digoxin may be added in about cases, and aldosterone inhibitors frequently are used in severe cases of heart failure. Beta-blocking remedys have different pharmacologic profiles, and the optimal agent has not been determined. Poole-Wilson and colleagues directioned the large, multicenter Carvedilol Or Metoprolol European Trial to compare the efficacy of the sum of two units agents in the treatment of patients with mild to rigid chronic heart failure.

The cogitation involved 3,029 patients in 15 countries between 1996 and 1999 with follow-up until 2002 Patients included in the research had confirmed symptomatic chronic heart failure (New York Heart Association classes II to IV) and had been treated with diuretics for at least sum of two units weeks and ACE inhibitors for at least four weeks. Patients who had contraindications to beta blocker or unstable angina, myocardial infarction, or coronary revascularization or misfortune within the previous two month were exclud from the inquiry After baseline assessment, 1,511 patients were assigned to carvedilol (3125 mg twice daily) and 1518 patients were assigned to metoprolol (5 mg twice daily). The dose of each agent was titrated to achieve a target dosage of 25 mg twice daily of carvedilol or 50 mg twice daily of metoprolol. Patients were assessed each two weeks during the physic titration phase, then every four month during the maintenance phase. Patients were asked to report any adverse adventures and were followed for mortality or hospital admission.

The baseline characteristics of the sum of two units groups were comparable, and small equivalent numbers in each cluster withdrew consent or were missing to follow-up. Fewer patients treated with carvedilol (512) died than those treated with metoprolol (600); this benefit in mortality was apparent after six month of treatment. The majority of deaths among patients in the two groups were attributed to quickly prepared death caused by circulatory failure. Rates of hospital admission were similar between the couple treatment groups (see accompanying table). Adverse weights were reported by more than 90 percent of patients in as well-as; not only-but also; not only-but; not alone-but groups, and 75 percent of those receiving carvedilol and 77 percent of those receiving metoprolol reported at least common serious adverse event. Slightly more than common half of the patients had at least united serious cardiovascular adverse event in the same state [i]or[/i] condition as bradycardia or hypotension. In as well-as; not only-but also; not only-but; not alone-but groups, 32 percent of patients stopped taking the cogitation drug.

The authors judge that carvedilol has a greater benefit than metoprolol when added to diuretic and ACE inhibitor therapy in the treatment of heart failure. This may be the consequence of the difference in the receptors fill uped or other effects of carvedilol, in the same state [i]or[/i] condition as increased insulin sensitivity and antioxidant import on endothelial function.

Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol upon clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controll trial. Lancet July 5 2003;362:7-13

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group